Orphazyme A/S provides update on previously announced global offering
Sep 25, 2020
Orphazyme A/S (ORPHA.CO) (the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced an update on its previously announced global offering. On September 24, 2020, the Company received a filing communication from the U.S. Food and Drug Administration (FDA) in connection with its new drug application (NDA) for arimoclomol for the treatment of Niemann-Pick disease Type C. The FDA letter follows acceptance on a Priority Review basis by the FDA of the Company’s NDA for arimoclomol in NPC and the FDA’s establishment of the Prescription Drug User Fee Act (“PDUFA”) target action date of March 17, 2021. The Company’s receipt of the filing communication does not impact the FDA’s acceptance of the Company’s NDA, the target PDUFA action date or the FDA’s Priority Review determination.
Orphazyme as provides update on previously announced
Read moreNew incentive program for the Board of Directors of Orphazyme
Sep 21, 2020
Orphazyme A/S (ORPHA.CO) (the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that the Company introduces a new Board Incentive Program for the Company’s members of the Board of Directors, as approved at the Company’s Extraordinary General Meeting held on September 21, 2020.
New incentive program for the board of directors of
Read moreOrphazyme A/S commences a global offering, consisting of initial public offering of ADSs in the U.S. and concurrent private placement of ordinary shares in Europe
Sep 21, 2020
Orphazyme A/S (ORPHA.CO) (the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that it has commenced a global offering of up to 7,616,146 new ordinary shares, consisting of an initial public offering of American Depositary Shares ("ADSs") representing ordinary shares of the Company in the U.S. (the "U.S. Offering") and a concurrent private placement of ordinary shares in Europe (the "European Private Placement" and together with the U.S. Offering, the "Offering").
Orphazyme as commences a global offering
Read moreResolutions passed at the Extraordinary General Meeting
Sep 21, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering the -Shock Protein response for the treatment of neurodegenerative orphan diseases, today held an Extraordinary General Meeting, at which the Extraordinary General Meeting.
Resolutions passed at the extraordinary general meeting
Read moreOrphazyme announces U.S. FDA acceptance and Priority Review of New Drug Application for arimoclomol for Niemann-Pick disease Type C
Sep 16, 2020
Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted, with Priority Review, the company’s New Drug Application (NDA) for arimoclomol for the treatment of NPC.
Orphazyme announces u s fda acceptance and priority
Read moreOrphazyme files registration statement in the U.S. in connection with proposed global offering, consisting of initial public offering of ADSs in the U.S. and concurrent private placement of ordinary shares in Europe
Sep 4, 2020
Orphazyme A/S (ORPHA.CO) (the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that it has filed a registration statement on Form F-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed registered initial public offering of the Company’s ordinary shares, to be delivered in the form of American Depositary Shares (“ADSs”), in the United States, as well as a concurrent private placement of ordinary shares (together with the ADSs, the "Securities") to certain qualified investors in Europe. The number and price of the Securities to be sold in the offering has not yet been determined.
Orphazyme files registration statement
Read moreCapital increase of 1,927 shares in Orphazyme A/S as a result of the exercise of Restricted Share Units
Sep 1, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces that a share capital increase has been registered with the Danish Business Authority as a result of the exercise of Restricted Share Units by board members. A total of 1,927 shares of nominally DKK 1 each have been issued by the Company at a subscription price per Restricted Share Unit of DKK 61.1895.
Capital increase of 1 927 shares in Orphazyme
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Sep 1, 2020
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.
Reporting of transactions in orphazymes shares made
Read moreNotice to convene Extraordinary General Meeting in Orphazyme A/S
Aug 28, 2020
Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the amplification of the Heat-Shock Proteins in order to develop and commercialize novel therapeutics for the treatment of neurodegenerative orphan diseases, today announced.
Read moreOrphazyme announces Interim Report First Half 2020
Aug 28, 2020
Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces its Interim Report First Half 2020 for the period January 1–June 30, 2020.
Orphazyme announces interim report first half 2020
Read more